Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accord Healthcare Ltd.

https://www.accord-healthcare.com/

Latest From Accord Healthcare Ltd.

Accord Seeks To Capitalize On Portfolio And Partnerships

Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.

Strategy Generic Drugs

EU Approvals Beckon For Inrebic & Novel Adalimumab Biosimilar

Inrebic, Celgene’s myelofibrosis treatment, and Yuflyma, Celltrion’s high-concentration adalimumab biosimilar, are among the latest new drugs that have been recommended for approval for use across the EU. Meanwhile, TETEC has withdrawn its EU marketing application for Artobend.

Europe Approvals

Accord Expands CNS Ambitions With Zubsolv Deal

Accord Healthcare has struck a European licensing deal with Orexo for its Zubsolv opioid-dependence treatment, building on a CNS business that also includes a recent distribution agreement with Molteni Farmaceutici for Sixmo.

Deals Strategy

Troubled Bayer Boosted By Big Two Pharma Earners

While the legal woes over the seeds giant Monsanto continue, the German group's pharmaceuticals business posts unspectacular third quarter results.

Sales & Earnings Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register